FY2026 EPS Estimates for Halozyme Therapeutics, Inc. Raised by Zacks Research (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Investment analysts at Zacks Research lifted their FY2026 earnings estimates for shares of Halozyme Therapeutics in a research note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $5.16 per share for the year, up from their prior forecast of $5.08. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.45 per share.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million.

HALO has been the topic of a number of other reports. StockNews.com upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, February 23rd. Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an "overweight" rating on the stock in a report on Tuesday, December 26th. JMP Securities restated a "market outperform" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. The Goldman Sachs Group decreased their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating for the company in a research report on Thursday, January 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average price target of $53.29.

Halozyme Therapeutics Stock Up 0.4 %

Shares of NASDAQ:HALO traded up $0.15 during midday trading on Wednesday, reaching $39.12. 620,516 shares of the company were exchanged, compared to its average volume of 1,244,815. Halozyme Therapeutics has a fifty-two week low of $29.85 and a fifty-two week high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The stock has a fifty day simple moving average of $39.71 and a two-hundred day simple moving average of $37.79. The firm has a market cap of $4.97 billion, a PE ratio of 18.54, a P/E/G ratio of 0.45 and a beta of 1.25.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares of the company's stock, valued at approximately $6,519,075.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 30,000 shares of company stock valued at $1,196,800 in the last quarter. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Rise Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth about $25,000. Principal Securities Inc. bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $34,000. First Horizon Advisors Inc. boosted its holdings in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 293 shares during the period. Parkside Financial Bank & Trust bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $64,000. Finally, Headlands Technologies LLC boosted its holdings in shares of Halozyme Therapeutics by 1,068.2% during the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company's stock worth $65,000 after buying an additional 1,613 shares during the period. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.